New Strategies for Medical Management of Castration-Resistant Prostate Cancer

Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study

(2010) Jean-Christophe Eymard et al.   BJU INTERNATIONAL

A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy

(2010) P. Mathew et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

(2010) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Studies of Drug Combinations

(2010) Jaap Verweij et al.   JOURNAL OF CLINICAL ONCOLOGY

[18F]Fluorodeoxyglucose Positron Emission Tomography in the Initial Staging of Squamous Cell Carcinoma of the Head and Neck: Promise, Evidence, and Reality

(2010) Jonas A. de Souza et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

(2010) Daniel C. Danila et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

(2010) Howard I Scher et al.   LANCET

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors

(2010) Anders Olsson et al.   Molecular Cancer

VEGF Inhibitors and Prostate Cancer Therapy

(2010) Jeanny Aragon-Ching et al.   Current Molecular Pharmacology

Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer

(2009) M. D. Galsky et al.   ANNALS OF ONCOLOGY

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer

(2009) O Bratt et al.   BRITISH JOURNAL OF CANCER

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

(2009) A. C. Mita et al.   CLINICAL CANCER RESEARCH

Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors

(2009) Quincy Siu-Chung Chu   EXPERT OPINION ON BIOLOGICAL THERAPY

Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line

(2009) Gemma Marcias et al.   HUMAN MUTATION

Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

(2009) Gerhardt Attard et al.   JOURNAL OF CLINICAL ONCOLOGY

Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial

(2009) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer

(2009) William L. Dahut et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE

Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer

(2008) A. Hussain et al.   ANNALS OF ONCOLOGY

Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa

(2008) D. R. Berthold et al.   ANNALS OF ONCOLOGY

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

(2008) X. Pivot et al.   ANNALS OF ONCOLOGY

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

(2008) Joel B. Nelson et al.   CANCER

Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells

(2008) B KARABULUT et al.   CELL BIOLOGY INTERNATIONAL

A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer

(2008) A. J. Armstrong et al.   CLINICAL CANCER RESEARCH

Targeting CYP17: established and novel approaches in prostate cancer

(2008) Timothy A Yap et al.   CURRENT OPINION IN PHARMACOLOGY

Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study

(2008) Giuseppe Di Lorenzo et al.   EUROPEAN UROLOGY

Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial

(2008) Nicholas D. James et al.   EUROPEAN UROLOGY

Pleiotropic functional properties of androgen receptor mutants in prostate cancer

(2008) Jean-Pierre Bergerat et al.   HUMAN MUTATION

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

(2008) Dominik R. Berthold et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

(2008) Gerhardt Attard et al.   JOURNAL OF CLINICAL ONCOLOGY

Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone

(2008) Orazio Caffo et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS